Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702059 | 0.95 | HTT (0.46) | HTTCES2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11211947 | 0.81 | HTR2A (0.53) | CYP2D6SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL7271568 | 0.81 | HTT (0.36) | HTTCYP2D6SLC6A2SLC6A4DRD2 | |
| SCHEMBL7270702 | 0.81 | OPRM1 (0.40) | CYP2D6ALDH1A1SLC6A2SLC6A4HTR2A | |
| SCHEMBL28758384 | 0.80 | SLC6A2 (0.40) | HTTCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL7405300 | 0.77 | HTR2A (0.50) | CYP2D6SLC6A2SLC6A4DRD2HTR2A | |
| SCHEMBL28123567 | 0.76 | L3MBTL4 (0.41) | CES2CYP2D6ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL9419926 | 0.74 | CES2 (0.47) | CES2 | |
| SCHEMBL17193849 | 0.73 | LMNA (0.40) | CYP2D6ALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL7271833 | 0.73 | SLC6A2 (0.37) | HTTCYP2D6ALDH1A1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | claimed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | claimed |
| US-7192939-B2 | Pestalotiopsis microsporia isolates and compounds derived therefrom | MONTANA STATE UNIVERSITY (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2003064617-A9 | PESTALOTIOPSIS MICROSPORIA ISOLATES AND COMPOUNDS DERIVED THEREFROM | UNIV MONTANA STATE (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040009573-A1 | A biologically pure culture of Pestalotiopsis microspora strain 12-30 characterized by possessing antioxidant and antifungal activities in culture media, and containing 1,5,7 trisubstituted 1,3-dihydroisobenzofurans | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-15 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009573-A1 | A biologically pure culture of Pestalotiopsis microspora strain 12-30 characterized by possessing antioxidant and antifungal activities in culture media, and containing 1,5,7 trisubstituted 1,3-dihydroisobenzofurans | CYP51A1, PRDX3, PRDX5 | HTT 3928/4885CES2 3787/4885CYP2D6 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.